Please ensure Javascript is enabled for purposes of website accessibility

DioGenix raises funds for product test

DioGenix Inc., of Gaithersburg, a developer of novel molecular tests focused on immune-related neurological diseases and disorders, said it raised $3.2 million in funding from existing and new investors to finance completion of the largest clinical diagnostic trial of its kind for multiple sclerosis.

The study’s aim is to validate the performance of DioGenix’s MS Precise, a next-generation sequencing assay that has shown it can accurately identify patients with multiple sclerosis at first clinical presentation.

DioGenix also announced it has established a new central laboratory that will serve as the basis for future commercialization of MS Precise following regulatory licensure.